Noteworthy Price Action: Zafgen Inc Can’t Burn Your Long Portfolio. Has Another Strong Session

Noteworthy Price Action: Zafgen Inc Can't Burn Your Long Portfolio. Has Another Strong Session

The stock of Zafgen Inc (NASDAQ:ZFGN) is a huge mover today! The stock increased 5.44% or $0.18 during the last trading session, hitting $3.49. About 361,847 shares traded hands or 12.94% up from the average. Zafgen Inc (NASDAQ:ZFGN) has declined 47.12% since February 29, 2016 and is downtrending. It has underperformed by 59.34% the S&P500.
The move comes after 6 months positive chart setup for the $98.66M company. It was reported on Oct, 4 by We have $6.67 PT which if reached, will make NASDAQ:ZFGN worth $89.78M more.

Analysts await Zafgen Inc (NASDAQ:ZFGN) to report earnings on November, 8. They expect $-0.65 earnings per share, up 10.96% or $0.08 from last year’s $-0.73 per share. After $-0.55 actual earnings per share reported by Zafgen Inc for the previous quarter, Wall Street now forecasts 18.18% negative EPS growth.

Zafgen Inc (NASDAQ:ZFGN) Ratings Coverage

Out of 8 analysts covering Zafgen Inc (NASDAQ:ZFGN), 1 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 13% are positive. Zafgen Inc has been the topic of 16 analyst reports since August 25, 2015 according to StockzIntelligence Inc. RBC Capital Markets downgraded Zafgen Inc (NASDAQ:ZFGN) on Wednesday, December 2 to “Sector Perform” rating. The stock of Zafgen Inc (NASDAQ:ZFGN) earned “Buy” rating by Canaccord Genuity on Friday, November 13. The firm has “Mkt Perform” rating given on Thursday, December 3 by Leerink Swann. The stock of Zafgen Inc (NASDAQ:ZFGN) has “Neutral” rating given on Thursday, December 3 by SunTrust. The rating was downgraded by JMP Securities to “Mkt Perform” on Monday, October 19. On Thursday, October 15 the stock rating was maintained by RBC Capital Markets with “Outperform”. RBC Capital Markets upgraded Zafgen Inc (NASDAQ:ZFGN) rating on Thursday, January 21. RBC Capital Markets has “Outperform” rating and $21 price target. The stock of Zafgen Inc (NASDAQ:ZFGN) has “Buy” rating given on Monday, October 19 by SunTrust. The stock of Zafgen Inc (NASDAQ:ZFGN) earned “Hold” rating by Canaccord Genuity on Thursday, March 10. The rating was downgraded by Cowen & Co to “Market Perform” on Wednesday, July 20.

According to Zacks Investment Research, “Zafgen, Inc. is a biopharmaceutical company. The Company develops therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection that is in Phase II clinical trials for the treatment of various indications comprising obesity and hyperphagia in Prader-Willi Syndrome patients, craniopharyngioma-associated obesity, and severe obesity in the general population. Zafgen, Inc. is headquartered in Cambridge, Massachusetts.”

More notable recent Zafgen Inc (NASDAQ:ZFGN) news were published by: which released: “Zafgen shares drop more than 40% as drug focus shifted” on July 19, 2016, also with their article: “Why Zafgen Inc’s Stock Is in the Red Today” published on January 25, 2016, published: “Zafgen to scrap lead obesity drug, shares slide” on July 19, 2016. More interesting news about Zafgen Inc (NASDAQ:ZFGN) were released by: and their article: “Zafgen ends obesity drug trial after patient death” published on October 22, 2015 as well as‘s news article titled: “Zafgen Obesity Drug Trial on Hold After Second Patient Death” with publication date: December 02, 2015.

ZFGN Company Profile

Zafgen, Inc., incorporated on November 22, 2005, is a biopharmaceutical company. The Firm is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment